Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 4. Reported cases of notifiable diseases and rates per 100,000, by age, excluding U.S. territories - - United States, 2016
Disease <1 yr 1-4 yrs 5-14 yrs 15-24 yrs 25-39 yrs 40-64 yrs ≥65 yrs Age not stated Total
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. No.
Anthrax
Arboviral diseases
Chikungunya virus disease 2 0.01 8 0.02 17 0.04 68 0.10 112 0.11 38 0.08 2 247
Eastern equine encephalitis virus disease
Neuroinvasive 1 0.00 1 0.00 2 0.00 3 0.01 7
Non-neuroinvasive
Jamestown Canyon virus disease
Neuroinvasive 2 0.00 3 0.00 2 0.00 7
Non-neuroinvasive 1 0.00 3 0.00 4 0.01 8
La Crosse virus disease
Neuroinvasive 6 0.04 19 0.05 3 0.00 1 0.00 2 0.00 31
Non-neuroinvasive 2 0.01 1 0.00 1 0.00 4
Powassan virus disease
Neuroinvasive 1 0.03 9 0.01 11 0.02 21
Non-neuroinvasive 1 0.00 1
St. Louis encephalitis virus disease
Neuroinvasive 3 0.00 4 0.01 7
Non-neuroinvasive 1 0.00 1
West Nile virus disease
Neuroinvasive 4 0.03 19 0.05 45 0.10 145 0.22 581 0.56 514 1.04 1,308
Non-neuroinvasive 2 0.01 16 0.04 47 0.11 155 0.24 453 0.44 168 0.34 841
Western equine encephalitis virus disease
Neuroinvasive
Non-neuroinvasive
Babesiosis
Total 8 0.07 37 0.13 41 0.13 158 0.34 794 1.07 865 2.54 7 1,910
Confirmed 5 0.04 27 0.09 28 0.09 126 0.27 620 0.84 772 2.27 7 1,585
Probable 3 0.03 10 0.03 13 0.04 32 0.07 174 0.24 93 0.27 325
Botulism
Total 140 3.53 1 0.01 3 0.01 23 0.04 21 0.02 9 0.02 4 201
Foodborne 1 0.01 3 0.01 13 0.02 8 0.01 6 0.01 31
Infant * 140 3.53 4 144
Other (wound & unspecified) 10 0.02 13 0.01 3 0.01 26
Brucellosis 2 0.01 10 0.02 3 0.01 29 0.04 59 0.06 23 0.05 1 127
Campylobacteriosis 1,762 44.38 5,703 35.74 4,897 11.93 6,809 15.65 10,835 16.55 19,081 18.36 10,922 22.18 111 60,120
Chancroid 2 0.00 4 0.01 1 0.00 7
Chlamydia trachomatis infection 482 12.14 114 0.71 10,759 26.21 1,008,403 2,317.58 497,907 760.73 74,185 71.37 1,772 3.60 4,732 1,598,354
Cholera 2 0.00 3 0.00 7 0.01 3 0.01 15
Coccidioidomycosis  7 0.43 53 0.81 491 2.91 1,097 6.15 2,320 8.69 4,948 11.81 2,898 14.69 15 11,829
Cryptosporidiosis
Total 200 5.04 1,842 11.54 2,212 5.39 1,862 4.28 3,254 4.97 2,797 2.69 1,225 2.49 61 13,453
Confirmed 131 3.30 1,259 7.89 1,503 3.66 1,205 2.77 2,054 3.14 1,790 1.72 664 1.35 31 8,637
Probable 69 1.74 583 3.65 709 1.73 657 1.51 1,200 1.83 1,007 0.97 561 1.14 30 4,816
Cyclosporiasis 5 0.03 10 0.03 38 0.10 124 0.21 277 0.29 77 0.17 6 537
Dengue virus infections §
Dengue 1 0.03 6 0.04 39 0.10 134 0.31 275 0.42 362 0.35 86 0.17 903
Dengue-like illness 1 0.01 1 0.00 7 0.02 14 0.02 10 0.01 3 0.01 4 40
Severe dengue 1 0.00 1 0.00 1 0.00 6 0.01 1 0.00 10
Diphtheria
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 1 0.03 18 0.12 107 0.27 147 0.35 361 0.57 1,914 1.91 1,596 3.35 7 4,151
Ehrlichia chaffeensis infection 1 0.03 6 0.04 46 0.12 87 0.21 153 0.24 610 0.61 466 0.98 8 1,377
Ehrlichia ewingii infection 2 0.00 9 0.01 11 0.02 22
Undetermined ehrlichiosis/anaplasmosis 3 0.02 15 0.04 15 0.04 36 0.06 76 0.08 54 0.11 1 200
Giardiasis 104 3.40 1,607 13.06 1,911 6.04 1,880 5.54 3,461 6.76 5,297 6.46 1,991 5.03 59 16,310
Gonorrhea 95 2.39 92 0.58 2,534 6.17 218,302 501.72 192,987 294.86 51,384 49.43 1,599 3.25 1,521 468,514
Haemophilus influenzae, invasive disease
All ages, all serotypes 351 8.84 221 1.38 128 0.31 120 0.28 315 0.48 1,209 1.16 2,546 5.17 5 4,895
Age <5 years 
Serotype b 19 0.48 11 0.07 30
Non-b serotype 78 1.96 81 0.51 159
Nontypeable 137 3.45 59 0.37 196
Unknown serotype 117 2.95 70 0.44 187
Hansen's disease 3 0.01 4 0.01 7 0.01 29 0.03 18 0.04 17 78
Hantavirus infection, non-hantavirus pulmonary syndrome 1 0.00 1 0.00 2 0.00 2 0.00 6
Hantavirus pulmonary syndrome 2 0.00 4 0.01 7 0.01 12 0.01 6 0.01 31
Hemolytic uremic syndrome post-diarrheal 9 0.23 143 0.92 100 0.25 13 0.03 10 0.02 11 0.01 19 0.04 2 307
Hepatitis **
A, acute 1 0.03 18 0.11 59 0.14 265 0.61 618 0.94 738 0.71 301 0.61 7 2,007
B, acute 1 0.03 4 0.01 107 0.25 1,192 1.84 1,705 1.65 198 0.40 11 3,218
B, perinatal infection †† 17 0.43 15 0.38 32
C, acute 7 0.19 3 0.02 531 1.30 1,528 2.47 784 0.80 68 0.15 21 2,942
Human immunodeficiency virus diagnoses 39 0.98 15 0.09 67 0.16 7,243 16.65 15,630 23.88 11,052 10.63 729 1.48 34,775
Influenza-associated pediatric mortality §§ 8 0.20 26 0.16 39 0.10 9 0.07 82
Invasive pneumococcal disease
All ages 395 13.42 717 6.05 464 1.52 315 0.97 1,425 2.96 7,305 9.40 6,972 18.68 33 17,626
Confirmed 393 13.35 715 6.04 464 1.52 315 0.97 1,425 2.96 7,299 9.39 6,959 18.64 33 17,603
Probable 2 0.07 2 0.02 6 0.01 13 0.03 23
Age <5 years  408 12.86 734 5.75 1,142
Confirmed 406 12.80 731 5.72 1,137
Probable 2 0.06 3 0.02 5
Legionellosis 3 0.08 2 0.01 4 0.01 61 0.14 398 0.61 2,927 2.82 2,742 5.57 4 6,141
Leptospirosis 3 0.01 11 0.03 17 0.03 36 0.05 11 0.03 78
Listeriosis 34 0.86 1 0.01 5 0.01 20 0.05 61 0.09 183 0.18 480 0.97 2 786
Lyme disease
Total 21 0.53 1,283 8.08 5,776 14.13 3,495 8.07 4,822 7.40 12,970 12.53 7,360 15.02 702 36,429
Confirmed 20 0.51 1,074 6.76 4,472 10.94 2,343 5.41 3,311 5.08 9,355 9.04 5,045 10.30 583 26,203
Probable 1 0.03 209 1.32 1,304 3.19 1,152 2.66 1,511 2.32 3,615 3.49 2,315 4.72 119 10,226
Malaria 8 0.20 91 0.57 194 0.47 258 0.59 568 0.87 702 0.68 132 0.27 2 1,955
Measles
Total 5 0.13 9 0.06 14 0.03 16 0.04 26 0.04 15 0.01 85
Indigenous 4 0.10 7 0.04 8 0.02 15 0.03 21 0.03 13 0.01 68
Imported 1 0.03 2 0.01 6 0.01 1 0.00 5 0.01 2 0.00 17
Meningococcal disease
All serogroups 35 0.88 33 0.21 21 0.05 80 0.18 64 0.10 80 0.08 62 0.13 375
Serogroups ACWY 5 0.13 16 0.10 6 0.01 14 0.03 16 0.02 39 0.04 30 0.06 126
Serogroup B 18 0.45 10 0.06 6 0.01 25 0.06 11 0.02 8 0.01 8 0.02 86
Other serogroups 1 0.03 2 0.01 1 0.00 6 0.01 5 0.01 4 0.00 2 0.00 21
Unknown serogroup 11 0.28 5 0.03 8 0.02 35 0.08 32 0.05 29 0.03 22 0.04 142
Mumps 16 0.40 192 1.20 1,623 3.95 2,716 6.24 1,125 1.72 626 0.60 62 0.13 9 6,369
Novel Influenza A virus infections 1 0.03 6 0.04 9 0.02 2 0.00 4 0.00 1 23
Pertussis 2,020 50.88 2,435 15.26 5,833 14.21 3,998 9.19 1,094 1.67 1,905 1.83 657 1.33 30 17,972
Plague 2 0.00 2 0.00 4
Poliomyelitis, paralytic
Poliovirus infection, nonparalytic
Psittacosis 2 0.01 3 0.01 5 0.01 2 0.00 12
Q fever
Total 1 0.01 2 0.00 6 0.01 25 0.04 89 0.09 41 0.08 164
Acute 1 0.01 2 0.00 5 0.01 21 0.03 72 0.07 31 0.06 132
Chronic 1 0.00 4 0.01 17 0.02 10 0.02 32
Rabies
Human
Rubella 1 0.00 1
Rubella, congenital syndrome * 2 0.05 2
Salmonellosis 5,126 129.11 7,321 45.88 5,724 13.94 4,989 11.47 7,687 11.74 13,917 13.39 8,562 17.39 524 53,850
Severe acute respiratory syndrome-associated coronavirus disease
Shiga toxin-producing Escherichia coli ¶¶ 340 8.56 1,782 11.17 1,400 3.41 1,320 3.03 1,275 1.95 1,159 1.12 806 1.64 87 8,169
Shigellosis 289 7.28 5,181 32.47 6,035 14.70 1,642 3.77 3,722 5.69 3,144 3.02 984 2.00 100 21,097
Smallpox
Spotted fever rickettsiosis
Total 2 0.05 45 0.28 186 0.46 353 0.82 823 1.27 1,924 1.86 931 1.90 5 4,269
Confirmed 2 0.01 14 0.03 13 0.03 23 0.04 67 0.06 35 0.07 154
Probable 2 0.05 43 0.27 172 0.42 340 0.79 800 1.23 1,857 1.80 896 1.83 5 4,115
Streptococcal toxic shock syndrome 1 0.04 4 0.04 18 0.07 9 0.03 43 0.10 123 0.18 85 0.26 283
Syphilis
Total, all stages *** 634 15.97 4 0.03 42 0.10 17,544 40.32 41,556 63.49 26,306 25.31 1,867 3.79 89 88,042
Congenital * 628 15.82 628
Primary and secondary 2 0.01 17 0.04 6,470 14.87 13,498 20.62 7,511 7.23 279 0.57 37 27,814
Tetanus 5 0.01 2 0.00 9 0.01 6 0.01 3 0.01 9 34
Toxic shock syndrome (other than Streptococcal) 15 0.05 17 0.06 3 0.01 5 0.01 40
Trichinellosis 2 0.01 2 0.00 4 0.01 14 0.01 4 0.01 26
Tuberculosis 48 1.21 176 1.10 163 0.40 938 2.16 2,206 3.37 3,470 3.34 2,264 4.60 7 9,272
Tularemia 1 0.03 14 0.09 19 0.05 17 0.04 29 0.04 99 0.10 51 0.10 230
Typhoid fever 2 0.05 32 0.20 79 0.19 78 0.18 111 0.17 60 0.06 7 0.01 7 376
Vancomycin-intermediate Staphylococcus aureus 1 0.03 1 0.01 2 0.01 4 0.01 15 0.03 48 0.06 37 0.10 108
Vancomycin-resistant Staphylococcus aureus
Varicella morbidity 768 23.90 1,927 14.95 3,228 9.75 912 2.60 822 1.55 577 0.69 112 0.29 607 8,953
Varicella mortality U U U U U U U U U U U U U U U U
Vibriosis
Total 3 0.08 25 0.16 121 0.30 93 0.22 194 0.30 495 0.48 335 0.69 7 1,273
Confirmed 2 0.05 23 0.15 120 0.30 93 0.22 184 0.29 491 0.48 325 0.67 3 1,241
Probable 1 0.03 2 0.01 1 0.00 10 0.02 4 0.00 10 0.02 4 32
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus
Ebola virus
Guanarito virus
Junin virus
Lassa virus
Lujo virus
Machupo virus
Marburg virus
Sabia virus
Yellow fever 1 0.00 1
Zika virus
Zika virus disease, congenital *,††† 25 0.63 5 30
Zika virus disease, non-congenital 3 0.08 22 0.14 180 0.44 764 1.76 1,810 2.77 2,077 2.00 272 0.55 4 5,132
Zika virus infection, congenital *,††† 29 0.73 16 45
Zika virus infection, non-congenital 1 0.03 6 0.01 295 0.68 545 0.83 51 0.05 12 0.02 1 911
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • U: Unavailable — The data are unavailable.
  • * The rate is calculated using population less than 1 year of age.
  • † Reportable in <25 states.
  • § Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
  • ¶ The rate is calculated using population less than 5 years of age.
  • ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm.
  • †† The rate is calculated using population less than 2 years of age.
  • §§ The rate is calculated using population less than 18 years of age.
  • ¶¶ Includes Escherichia coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.
  • *** Includes syphilis of all stages, including cases where stage of syphilis is not stated.
  • ††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.